{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:45:57Z","timestamp":1790646357664,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Auton Res"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10286-019-00626-8","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T12:03:30Z","timestamp":1565352210000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0934-9631","authenticated-orcid":false,"given":"Isabel","family":"Concei\u00e7\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,9]]},"reference":[{"key":"626_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","volume":"86","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y (2015) Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 86:1036\u20131043","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"626_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Plant\u00e9-Bordeneuve V, Rapezzi C, Said G, Salvi F (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8:31","journal-title":"Orphanet J Rare Dis"},{"issue":"7 Suppl","key":"626_CR3","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA (2017) Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care 23(7 Suppl):S107\u2013S112","journal-title":"Am J Manag Care"},{"issue":"1","key":"626_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o I, Gonz\u00e1lez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L (2016) \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21(1):5\u20139. \n                    https:\/\/doi.org\/10.1111\/jns.12153","journal-title":"J Peripher Nerv Syst"},{"key":"626_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/joim.12585","volume":"281","author":"OB Suhr","year":"2017","unstructured":"Suhr OB, Lundgren E, Westermark P (2017) One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med 281:337\u2013347","journal-title":"J Intern Med"},{"issue":"23","key":"626_CR6","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.2169\/internalmedicine.1113-18","volume":"57","author":"H Koike","year":"2018","unstructured":"Koike H, Nakamura T, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G (2018) Widespread cardiac and vasomotor autonomic dysfunction in non Val30Met hereditary transthyretin amyloidosis. Intern Med 57(23):3365\u20133370. \n                    https:\/\/doi.org\/10.2169\/internalmedicine.1113-18","journal-title":"Intern Med"},{"issue":"11","key":"626_CR7","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.4065\/83.11.1226","volume":"83","author":"AK Wang","year":"2008","unstructured":"Wang AK, Fealey RD, Gehrking TL, Low PA (2008) Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc 83(11):1226\u20131230","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"626_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40120-014-0023","volume":"3","author":"OB Suhr","year":"2014","unstructured":"Suhr OB, Concei\u00e7\u00e3o IM, Karayal ON, Mandel FS, Huertas PE, Ericzon BG (2014) Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis. Neurol Ther 3(2):101\u2013112. \n                    https:\/\/doi.org\/10.1007\/s40120-014-0023","journal-title":"Neurol Ther"},{"key":"626_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1750-1172-9-61","volume":"9","author":"J Wixner","year":"2014","unstructured":"Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB, THAOS investigators (2014) THAOS: gastrointestinal manifestations of transthyretin amyloidosis-common complications of a rare disease. Orphanet J Rare Dis 9:61. \n                    https:\/\/doi.org\/10.1186\/1750-1172-9-61","journal-title":"Orphanet J Rare Dis"},{"issue":"1\u20132","key":"626_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0022-510X(87)90267-X","volume":"79","author":"S Ikeda","year":"1987","unstructured":"Ikeda S, Yanagisawa N, Hongo M, Ito N (1987) Vagus nerve and celiac ganglion lesions in generalized amyloidosis. A correlative study of familial amyloid polyneuropathy and AL-amyloidosis. J Neurol Sci 79(1\u20132):129\u2013139","journal-title":"J Neurol Sci"},{"issue":"5","key":"626_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1046\/j.1365-2796.1999.00484.x","volume":"245","author":"I Anan","year":"1999","unstructured":"Anan I, El-Salhy M, Ando Y, Nyhlin N, Terazaki H, Sakashita N, Suhr O (1999) Colonic endocrine cells in patients with familial amyloidotic polyneuropathy. J Intern Med 245(5):469\u2013473","journal-title":"J Intern Med"},{"key":"626_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-018-0514-2","author":"A Gonzalez-Duarte","year":"2018","unstructured":"Gonzalez-Duarte A (2018) Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res. \n                    https:\/\/doi.org\/10.1007\/s10286-018-0514-2","journal-title":"Clin Auton Res"},{"issue":"2","key":"626_CR13","first-page":"201","volume":"23","author":"CA Coutinho","year":"2004","unstructured":"Coutinho CA, Concei\u00e7\u00e3o I, Almeida A, Cantinho G, Sargento L, Vagueiro MC (2004) Early detection of sympathetic myocardial denervation in patients with familial amyloid polyneuropathy type I. Rev Port Cardiol 23(2):201\u2013211","journal-title":"Rev Port Cardiol"},{"issue":"1","key":"626_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plant\u00e9-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Concei\u00e7\u00e3o I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. New Engl J Med 379(1):22\u201331","journal-title":"New Engl J Med"},{"issue":"1","key":"626_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plant\u00e9-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321. \n                    https:\/\/doi.org\/10.1056\/nejmoa1716153","journal-title":"N Engl J Med"},{"key":"626_CR16","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.3791\/2502","volume":"53","author":"P Novak","year":"2011","unstructured":"Novak P (2011) Quantitative autonomic testing. J Vis Exp 53:2502. \n                    https:\/\/doi.org\/10.3791\/2502","journal-title":"J Vis Exp"},{"key":"626_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25563","author":"PJ Dyck","year":"2017","unstructured":"Dyck PJ, Kincaid JC, Dyck PJB, Chaudhry V, Goyal NA, Alves C, Salhi H, Wiesman JF, Labeyrie C, Robinson-Papp J, Cardoso M, Laura M, Ruzhansky K, Cortese A, Brannagan TH, Khoury J, Khella S, Waddington-Cruz M, Ferreira J, Wang AK, Pinto MV, Ayache SS, Benson MD, Berk JL, Coelho T, Polydefkis M, Gorevic P, Adams DH, Plante-Bordeneuve V, Whelan C, Merlini G, Heitner S, Drachman BM, Concei\u00e7\u00e3o I, Klein CJ, Gertz MA, Ackermann EJ, Hughes SG, Mauermann ML, Bergemann R, Lodermeier KA, Davies JL, Carter RE, Litchy WJ (2017) Assessing mNIS+7 ionis and international neurologists\u2019 proficiency in a familial amyloidotic polyneuropathy trial. Muscle Nerve. \n                    https:\/\/doi.org\/10.1002\/mus.25563","journal-title":"Muscle Nerve"},{"issue":"1","key":"626_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","volume":"17","author":"D Adams","year":"2017","unstructured":"Adams D, Suhr OB, Dyck PJ, Litchy WJ, Leahy RG, Chen J, Gollob J, Coelho T (2017) Trial design and rationale for APOLLO, a phase 3, placebo controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol 17(1):181. \n                    https:\/\/doi.org\/10.1186\/s12883-017-0948-5","journal-title":"BMC Neurol"},{"issue":"3","key":"626_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mus.25257","volume":"55","author":"T Coelho","year":"2017","unstructured":"Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR (2017) Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve 55(3):323\u2013332. \n                    https:\/\/doi.org\/10.1002\/mus.25257","journal-title":"Muscle Nerve"},{"issue":"2","key":"626_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jns5.12059","volume":"19","author":"EJ Vinik","year":"2014","unstructured":"Vinik EJ, Vinik AI, Paulson JF, Merkies IS, Packman J, Grogan DR, Coelho T (2014) Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 19(2):104\u2013114. \n                    https:\/\/doi.org\/10.1111\/jns5.12059","journal-title":"J Peripher Nerv Syst"},{"issue":"7","key":"626_CR21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/ene.12717","volume":"22","author":"R Treister","year":"2015","unstructured":"Treister R, O\u2019Neil K, Downs HM, Oaklander AL (2015) Validation of the composite autonomic symptom scale 31 (COMPASS-31) in patients with and without small fiber polyneuropathy. Eur J Neurol 22(7):1124\u20131130. \n                    https:\/\/doi.org\/10.1111\/ene.12717","journal-title":"Eur J Neurol"},{"issue":"5","key":"626_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2796.1994.tb01106.x","volume":"235","author":"O Suhr","year":"1994","unstructured":"Suhr O, Danielsson A, Holmgren G, Steen L (1994) Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 235(5):479\u2013485","journal-title":"J Intern Med"},{"issue":"Supplement 2","key":"626_CR23","first-page":"16","volume":"25","author":"L Obici","year":"2018","unstructured":"Obici L, Coelho T, Gonzalez-Duarte A et al (2018) Impact of Patisiran on Norfolk Quality of Life Questionnaire diabetic neuropathy (QOL-DN) in patients with hereditary transthyretin-mediated amyloidosis: results from the phase 3 APOLLO study. Eur J Neurol 25(Supplement 2):16\u201389","journal-title":"Eur J Neurol"},{"key":"626_CR24","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2018-0033","author":"AV Kristen","year":"2018","unstructured":"Kristen AV, Ajroud-Driss S, Concei\u00e7\u00e3o I, Gorevic P, Kyriakides T, Obici L (2018) Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag. \n                    https:\/\/doi.org\/10.2217\/nmt-2018-0033","journal-title":"Neurodegener Dis Manag"},{"issue":"Supplement 2","key":"626_CR25","first-page":"16","volume":"25","author":"L Obici","year":"2018","unstructured":"Obici L, Coelho T, Adams D, Gonzalez-Duarte A, O\u2019Riordan W, Yang C-C, Yamashita T, Kristen A, Tournev I, Schmidt H, Berk J, Lin K-P, Gandhi P, Sweetser M, Chen J, Goyal S, Gollob J, Suhr O (2018) Impact of patisiran, an investigational RNAi therapeutic, on nutritional status in patients with hereditary transthyretin-mediated amyloidosis. Eur J Neurol 25(Supplement 2):16\u201389","journal-title":"Eur J Neurol"},{"issue":"11","key":"626_CR26","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00415-017-8629-2","volume":"264","author":"H Koike","year":"2017","unstructured":"Koike H, Nakamura T, Hashizume A, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G (2017) Cardiac and peripheral vasomotor autonomic functions in late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol 264(11):2293\u20132302. \n                    https:\/\/doi.org\/10.1007\/s00415-017-8629-2","journal-title":"J Neurol"},{"issue":"1","key":"626_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/17474124.2018.1397511","volume":"12","author":"J Wixner","year":"2018","unstructured":"Wixner J, Suhr OB, Anan I (2018) Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40\u00a0years. Expert Rev Gastroenterol Hepatol 12(1):73\u201381. \n                    https:\/\/doi.org\/10.1080\/17474124.2018.1397511","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"9","key":"626_CR28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1080\/003655200750023084","volume":"35","author":"K L\u00e5ng","year":"2000","unstructured":"L\u00e5ng K, Wikstr\u00f6m L, Danielsson A, Tashima K, Suhr OB (2000) Outcome of gastrointestinal complications after liver transplantation for familial amyloidotic polyneuropathy. Scand J Gastroenterol 35(9):985\u2013989","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"626_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/wnl.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plant\u00e9-Bordeneuve V, Lozeron P, Suhr O, Campistol JM, Concei\u00e7\u00e3o I, Schmidt HJ, Trigo P, Kelly J, Labaudini\u00e8re R, Chan J, Packman J, Wilson A, Grogan DR (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8):785\u2013792. \n                    https:\/\/doi.org\/10.1212\/wnl.0b013e3182661eb1","journal-title":"Neurology"},{"issue":"11","key":"626_CR30","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, da Silva AM, Cruz MW, Plant\u00e9-Bordeneuve V, Suhr OB, Concei\u00e7ao I, Schmidt HH, Trigo P, Kelly JW, Labaudini\u00e8re R, Chan J, Packman J, Grogan DR (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260(11):2802\u20132814. \n                    https:\/\/doi.org\/10.1007\/s00415-013-7051-7","journal-title":"J Neurol"},{"issue":"5","key":"626_CR31","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","volume":"263","author":"A Cortese","year":"2016","unstructured":"Cortese A, Vita G, Luigetti M et al (2016) Monitoring effectiveness and safety of tafamidis in a transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol 263(5):916\u2013924. \n                    https:\/\/doi.org\/10.1007\/s00415-016-8064-9","journal-title":"J Neurol"}],"container-title":["Clinical Autonomic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-019-00626-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10286-019-00626-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-019-00626-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T19:28:12Z","timestamp":1596828492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10286-019-00626-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,9]]},"references-count":31,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1007\/s10286-019-00626-8","relation":{},"ISSN":["0959-9851","1619-1560"],"issn-type":[{"value":"0959-9851","type":"print"},{"value":"1619-1560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,9]]},"assertion":[{"value":"26 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Concei\u00e7\u00e3o has been advisor to and investigator in clinical trials funded by Akcea, Alnylam and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}